Investigational drug for breast cancer patients with brain metastases

Trial ID:
IRB-25-8588
Tresa McGranahan, MD PhD

Inclusion Criteria

Patients must:

  • Be at least 18 years old
  • Have histologically confirmed HER2- metastatic brain cancer and at least one measurable intracranial lesion
  • Have 0-3 prior lines of chemotherapy in advanced or metastatic setting

Exclusion Criteria

Patients must not:

  • Have leptomeningeal metastasis confirmed by MRI and/or cerebrospinal fluid cytology
  • Have any intracranial lesion thought to require immediate local therapy, including (but not limited to) a lesion in an anatomic site where increase in size or possible treatment-related edema may pose risk to patient (e.g. brain stem lesions)
  • Have had evidence of intracranial hemorrhage within 12 months before study treatment

Additional Info

All treatments and physician visits during this study will take place at Scripps Clinic Torrey Pines/Green Hospital in La Jolla and Scripps Prebys Cancer Center/Mercy Hospital in Hillcrest.

For more details search for the NCT #, NCT06764940, on the ClinicalTrials.gov website (https://clinicaltrials.gov).

Contact Info:

  • Clinical Research Services
  • CRSLeadership@scrippshealth.org